• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
7.49% $13.20

NEUREN PHARMACEUTICALS LIMITED - Charts / Financials

Market Cap $1.687B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

refresh Created with Sketch. REFRESH
Day
Open $12.43   Day High $13.31   Day Low $12.42
Daily Volume 706677
Bids   Sellers
Number Price Volume   Number Price Volume
1 $13.18 7261   3 $13.20 13847

Directors & Senior Management

Mr. Jonathan Charles Pilcher Chief Executive Officer, Managing Director, Executive Director
Ms. Lauren Frazer Chief Financial Officer, Company Secretary
Mr. Larry Glass Chief Science Officer
Dr. Clive Blower Vice President - Product Development
Mr. Gerry Zhao Vice President - Corporate Development
Ms. Liza Squires Chief Medical Officer
Mr. Patrick Donald Davies Non-Executive Independent Chairman of the Board
Ms. Dianne Angus Non-Executive Independent Director
Mr. Joseph Basile Non-Executive Independent Director
Dr. Jenny Lee Harry Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$13.20 		Change
0.920(7.49%) 		Mkt cap ! $1.687B
Open High Low Value Volume
$12.43 $13.31 $12.42 $9.172M 706.6K

Buyers (Bids)

No. Vol. Price($)
1 7261 $13.18
 

Sellers (Offers)

Price($) Vol. No.
$13.20 13847 3
View Market Depth
Last trade - 16.10pm 17/01/2025 (20 minute delay) ?

Top Stories

Rio shares drop 1% on talk of Glencore merger

Rio Tinto has been trading down on reports that the mining titan could be in merger discussions with Glencore.
Lynas sales revenues up in Q2 of FY 2025, but lower production fuels share price slump Lynas Rare Earths Ltd has seen its share price drop 5.5% after releasing quarterly activities report in which it noted lower production
HotCopper Highlights: Your most watched stocks for Week 3, 2025 Good afternoon and welcome back to HotCopper highlights for the third week of the year @ let’s get into it. Raiden Resources was by far the most viewed stock as long-awaited results from its WA lithium drilling campaign turned up a duster. The company expanded the program out of t...
GTI progresses scoping study and other assessment work at Lo Hema GTI Energy Ltd has started drilling for the development of groundwater monitoring wells at the Lo Hema uranium project in Wyoming
Week 3 Wrap: Trump 2.0 kicks off next week (where is RFK?); US CPI reassures markets; Israel-Hamas ceasefire and the Red Sea It will be a most interesting day to wake up on the 22nd in Australia. We will either wake up to a world where the President of the United States has begun arresting journalists, Democratic politicians and other anti-Trump advocates @ or a world where he hasn’t. That two-sided coi...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.